Vorasidenib(LuciVora)

Another NameVoranigo、沃拉西德尼、沃拉西地尼

Indications

Indicated for the treatment of adult and pediatric patients 12 years of age and older with Grade 2 astrocytoma or oligodendroglioma harboring an IDH1 or IDH2 mutation as detected by an FDA-approved te

Specs

40mg*30tabs/box

WhatsApp

Factory:Lucius Pharmaceuticals

Reg No.:03 L 1325/25

Inspection No.:533-25

Dosage form:Tablet

Indate:24 months

Warm tips:Please purchase and use the medication under pharmacist guidance as the outer packaging is for reference only and the information is intended for professionals.

Introduction of Vorasidenib

Vorasidenib is an oral dual inhibitor of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2), and is a targeted therapeutic agent.

Medicine-related columns

Instructions of Vorasidenib

Indicated Population

Indicated for patients 12 years of age and older with IDH1/2-mutant Grade 2 glioma.

Dosage and Administration

The recommended dosage in adults is 40 mg once daily; in pediatric patients, the dosage is adjusted by body weight (40 mg for ≥40 kg and 20 mg for <40 kg).

Use in Specific Populations

Patients of reproductive potential should use effective non-hormonal contraception; in patients with hepatic or renal impairment, monitor for adverse reactions and adjust the dosage as appropriate.

Overdosage

Specific management of overdosage is not explicitly mentioned in the document; use as directed by a physician.

Pharmacokinetics

Pharmacokinetic data show that oral absorption is affected by food; it is primarily metabolized by CYP1A2, with a half-life of approximately 10 days.

Recommended Articles

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More